PACTR202404544467702Not yet recruitingPhase 3
Seasonal R21 mass vaccination for malaria elimination (SERVAL)
ondon School of Hygiene and Tropical Medicine0 sites16,200 target enrollmentStarted: September 26, 2023Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 16,200
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 0 Month(s) to 23 Month(s) (—)
- Sex
- All
Inclusion Criteria
- •1.Age= 5 months.
- •2.Willingness to comply with trial procedures.
- •3.Individual written informed consent obtained at the beginning of the study.
Exclusion Criteria
- •1.Pregnancy
- •2.History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, e.g., Kathon, neomycin, betapropiolactone.
- •3.Any history of anaphylaxis in relation to vaccination.
- •4.Known chronic illness.
- •5.Any other significant disease, disorder or situation which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial.
Investigators
Similar Trials
Recruiting
Phase 3
Seasonal R21 Mass Vaccination for Malaria EliminationMalariaNCT06578572London School of Hygiene and Tropical Medicine16,200
Active, not recruiting
Phase 3
The acceptability of seasonal antimalarial medication in Korogho, Côte d'IvoireInfections and InfestationsUnspecified malariaMalariaISRCTN17164969Institut de Recherche en Sciences de la Santé1,701
Completed
Phase 1
Adenovirus Vaccine for MalariaPlasmodium Falciparum InfectionNCT00371189National Institute of Allergy and Infectious Diseases (NIAID)75
Not yet recruiting
Phase 3
Broad One Health Endectocide-based Malaria Intervention in Africa - BOHEMIA: A Phase III cluster-randomized, open-label, clinical trial to study the safety and efficacy of ivermectin mass drug administration to reduce malaria transmission in two African settings.MalariaPACTR202106695877303Barcelona Institute for GlobalHealth53,000
Completed
Phase 1
EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum MalariaPlasmodium Falciparum MalariaNCT01169077National Institute of Allergy and Infectious Diseases (NIAID)39